Antiretroviral Therapy Journal Articles

• People Living With HIV Experience Greater Age Advancement A new study examines the question of whether people living with HIV experience accentuated aging compared with HIV-negative individuals.
  AIDS, January 2019
• Features of American Indian/Alaska Native Adults in HIV Care American Indians/Alaska Natives have the 4th highest HIV infection rate of all racial/ethnic groups. What are the sociodemographic and behavioral barriers to optimal care for these patients?
  Morbidity & Mortality Weekly Report, January 2019
• Serum CrAg Test to Diagnose HIV Cryptococcal Meningitis Is the serum cryptococcal antigen test an effective tool for detecting cryptococcal meningitis in HIV patients?
  HIV Medicine, January 2019
• Advancing HIV Prevention Research for At-Risk Adolescents The inclusion of at-risk youth in HIV prevention research is crucial to advancing our understanding of the efficacy and safety of PrEP use in this population.
  JAIDS: Journal of Acquired Immune Deficiency Syndromes, January 2019
• HIV Virological Failure During DTG Maintenance Monotherapy Which factors may be associated with virological failure during dolutegravir monotherapy for HIV?
  HIV Medicine, January 2019
• Influenza-Specific Antibody Avidity in ART-Treated HIV A new study examined the sex differences relative to influenza-specific antibody avidity in ART-treated HIV.
  AIDS, January 2019
• Patient Adherence to DRV/r Combined With RAL or TDF/FTC Did patient adherence to these regimens influence the efficacy results of the NEAT001/ANRS143 trial?
  JAIDS: Journal of Acquired Immune Deficiency Syndromes, December 2018
• Real-world Effectiveness of Elbasvir/Grazoprevir in HCV This study evaluated the effectiveness of EBR/GZR among HCV-infected patients in a real-world clinical setting.
  Journal of Viral Hepatitis, December 2018
• Cost-Effectiveness of PrEP for HIV Prevention for Conception A new study examines the economic value of preexposure prophylaxis to help prevent the perinatal transmission of HIV. How does it compare with other conception strategies?
  AIDS, December 2018
• Resistance-associated Substitutions of HCV After DAA Failure This study investigated how resistance-associated substitutions evolved after DAA treatment failures in HCV-infected patients, and assessed the effect of those substitutions on viral fitness.
  Journal of Viral Hepatitis, November 2018
• Prevalence of PAD Is Higher in Persons Living With HIV Is HIV an independent risk factor for peripheral artery disease? This study investigates.
  JAIDS: Journal of Acquired Immune Deficiency Syndromes, November 2018
• Neurodevelopmental Outcomes in ART-Exposed Children A new study examines the possible association between in-utero exposure to antiretroviral drugs and the risk for neurodevelopmental disorders.
  AIDS, November 2018
• Dual Therapy With Raltegravir and a bPI in Pretreated HIV Might treatment with raltegravir-containing combinations provide a feasible option for HIV patients who have failed previous therapies?
  HIV Medicine, November 2018
• HIV Preexposure Prophylaxis, by Race and Ethnicity Is preexposure prophylaxis being sufficiently prescribed to those for whom it is indicated? The findings of this study highlight gaps in effective PrEP implementation efforts in the United States.
  Morbidity & Mortality Weekly Report, November 2018
• Decision Making in HIV-1 Post-Exposure Prophylaxis Which factors may influence prescription decisions for HIV post-exposure prophylaxis?
  HIV Medicine, November 2018
• Drug Resistance in Patients Who Acquired HIV in a PrEP Trial Might the initiation of preexposure prophylaxis during unrecognized acute HIV infection lead to antiretroviral resistance?
  AIDS, November 2018
• Novel Antivirals for Hepatitis C This review spotlights two novel pangenotypic regimens for HCV infection, SOF/VEL/VOX for patients previously treated with NS5A inhibitors, and G/P for patients with advanced kidney disease.
  Alimentary Pharmacology & Therapeutics, November 2018
• Switching to RPV/FTC/TAF From RPV/FTC/TDF or EFV/FTC/TDF Switching to a coformulated regimen containing tenofovir alafenamide may provide additional bone and renal benefits in HIV patients.
  HIV Medicine, November 2018
• Exposure to ART Drugs and Incidence of Hypertension in HIV Is there an association between specific antiretroviral drugs and an increased risk of hypertension?
  HIV Medicine, November 2018
• Time to Recognize HIV Infection as a Major CV Risk Factor A new study shows that cardiovascular disease has become a key contributor to mortality among individuals living with HIV--even in the setting of treated and suppressed HIV disease.
  Circulation, November 2018